MIRM Mirum Pharmaceuticals, Inc.

NASDAQ
$92.49

Mirum Pharmaceuticals, Inc. (MIRM) is expected to report earnings on February 2, 2027, after the market close. The consensus earnings estimate is a loss of $0.67 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +11.3% since its last earnings release on November 3, 2026.

Mirum Pharmaceuticals, Inc. Missed Consensus Estimates, Raises Guidance
Tuesday, November 3, 2026 · 4:01 PM ET
Earnings Date
4th Quarter, Dec 2026
Feb 2
Tuesday · 4:00 PM ET
Earnings Whisper
-
vs ($0.67)
Rev est $193.49M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $93.97

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare liver diseases.

Sector

Healthcare

Industry

Biotechnology

Held By 1 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.